Giulia Chiesa graduated in Chemistry and Pharmaceutical Technology and she specialized in Pharmacology at the University of Milan, Italy. She was trained in the lab of Guido Franceschini and Cesare R. Sirtori in the Institute of Pharmacological Sciences at the University of Milan, investigating the effect of different pharmacological treatments on the HDL system.
Then she was Assistant instructor in Helen Hobbs lab at the Department of Molecular Genetics directed by Michael S. Brown and Joseph L. Goldstein, at the Southwestern Medical Center, Dallas, Texas, USA, studying genetics, metabolism and pro-atherogenic role of apolipoprotein(a).

Giulia Chiesa is currently Associate Professor at the University of Milan, Italy, in the Department of Pharmacological and Biomolecular Sciences. She is author of 92 papers and over 50 oral communications at national and international meetings. Her research is mainly focused on the study of the anti-atherogenic potential of HDL apolipoproteins in genetically modified mice; the efficacy of innovative pharmacological treatments (recombinant proteins) on the progression/regression of atherosclerotic plaques; the impact of dietary or pharmacological treatments, including drug repositioning, on lipid/lipoprotein metabolism and atherosclerosis development; the identification of new possible molecular targets for atherosclerosis therapy through transcriptomic, lipidomic, metabolomic and miRNomic approaches.

Contributions

Non-classical risk factors: Transitioning from association to causality - Discussion and Q&A90th EAS Congress 2022Non-classical risk factors: Transitioning from association to causality